BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9310122)

  • 1. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL).
    Palestro G; Ponti R; Chiusa L; Chiarle R; Geuna M; Novero D; Freilone R; Pich A
    Eur J Haematol; 1997 Sep; 59(3):148-54. PubMed ID: 9310122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis and proliferative activity of non-Hodgkin's lymphomas: comparison with expression of bcl-2, p53 and c-myc proteins.
    Takano Y; Saegusa M; Ikenaga M; Okayasu I
    Pathol Int; 1997; 47(2-3):90-4. PubMed ID: 9088026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients.
    Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM
    Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma.
    Miracco C; Santopietro R; Biagioli M; Lazzi S; Nyongo A; Vatti R; Luzi P
    J Cutan Pathol; 1998 May; 25(5):244-51. PubMed ID: 9696289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53, Bcl-2 and C-Myc expressions in colorectal carcinoma associated with schistosomiasis in Egypt.
    Zalata KR; Nasif WA; Ming SC; Lotfy M; Nada NA; El-Hak NG; Leech SH
    Cell Oncol; 2005; 27(4):245-53. PubMed ID: 16308474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
    Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
    Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.
    Wang DG; Liu WH; Johnston CF; Sloan JM; Buchanan KD
    Am J Pathol; 1998 Jun; 152(6):1407-13. PubMed ID: 9626044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
    Klobusická M; Kusenda J; Babusíková O
    Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products.
    Langlois NE; Lamb J; Eremin O; Heys SD
    J Pathol; 1997 Aug; 182(4):392-7. PubMed ID: 9306959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
    Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
    J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between EBV infection and expression of cellular proteins c-Myc, Bcl-2, and Bax in gastric carcinomas.
    Lima MA; Ferreira MV; Barros MA; Pardini MI; Ferrasi AC; Mota RM; Rabenhorst SH
    Diagn Mol Pathol; 2008 Jun; 17(2):82-9. PubMed ID: 18382371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
    Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
    Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 18. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas.
    Mishra SK; Crasta JA
    Int J Gynecol Cancer; 2010 May; 20(4):537-41. PubMed ID: 20442586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
    Chen Y; Fang L; Zhang J; Li G; Ma M; Li C; Lyu J; Meng QH
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28282916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.